In summary, resistance to PI3Kβ/AKT inhibition in PTEN-null BC cells is conferred by loss of a specific genes in the PI3K/AKT/mTOR pathway (including INPPL1, PIK3R2 and TSC1/2), rather than genes associated with alterative signaling pathways. This evidence concerns the gene AKT1 and breast cancer.